WO2018184316A1 - Nano-nemifitide liquid phase preparation method - Google Patents

Nano-nemifitide liquid phase preparation method Download PDF

Info

Publication number
WO2018184316A1
WO2018184316A1 PCT/CN2017/092716 CN2017092716W WO2018184316A1 WO 2018184316 A1 WO2018184316 A1 WO 2018184316A1 CN 2017092716 W CN2017092716 W CN 2017092716W WO 2018184316 A1 WO2018184316 A1 WO 2018184316A1
Authority
WO
WIPO (PCT)
Prior art keywords
boc
trp
dpm
fmoc
gly
Prior art date
Application number
PCT/CN2017/092716
Other languages
French (fr)
Chinese (zh)
Inventor
陈学明
陈晓欢
宓鹏程
陶安进
袁建成
Original Assignee
深圳翰宇药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳翰宇药业股份有限公司 filed Critical 深圳翰宇药业股份有限公司
Publication of WO2018184316A1 publication Critical patent/WO2018184316A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the field of medicine, in particular to a method for preparing a liquid phase of nano-nonpeptide.
  • Nano-peptide is an analog of the brain endogenous polypeptide MIF-1, which can exert anti-monophasic depression by 5-HT reuptake, which greatly changes the reuptake of 5-HT. Pass the blood-brain barrier and clear it slowly in the brain.
  • the US company InnapMarma is conducting Phase III clinical trials, and its antidepressant activity and safety have been clinically confirmed.
  • Nano-peptide English name: nemifitide; molecular formula: C 33 H 43 FN 10 O 6 ; CAS: 173240-15-8; is a synthetic pentapeptide compound, the structure is 4-fluoro-L-phenylalanine Acyl-(trans) 4-hydroxy-L-prolyl-L-arginyl-glycyl-L-tryptophan, see below:
  • the object of the present invention is to provide a liquid phase preparation method of nano-peptide, which has mild synthesis conditions, simple process and stable process, and is suitable for industrial continuous production.
  • the synthetic route map is as follows:
  • the preparation method of the nano-peptide of the invention comprises the following steps:
  • an aspect of the present invention provides a method for preparing a liquid phase of nano-nonpeptide, which comprises the following steps:
  • Fmoc-Trp(Boc)-NH-Dpm was synthesized by Dpm-NH 2 and Fmoc-Trp(Boc)-OH under the action of a condensing agent, and the Fmoc protecting group was removed to obtain the intermediate 1H-Trp(Boc)- NH-Dpm;
  • the condensing agent is selected from one or more of HOBt, EDC.HCl, HATU, DCC, DIC, HBTU, HOAt, HOBt, PyBOP, BTC, preferably HOBt and EDC.HCl The combination.
  • the reagent for removing the Fmoc protecting group is a mixture of DBU and diethylamine.
  • the method further comprises a purification step, wherein the purification step is 7),
  • reverse phase high pressure liquid chromatography is carried out by using reverse phase octadecylsilane as a stationary phase and 0.1% aqueous acetic acid/acetonitrile as a mobile phase to collect a peak fraction of interest and lyophilizing. .
  • the solvent in steps 1) to 5) is independently selected from one or more of dichloromethane, chloroform, toluene, preferably chloroform.
  • the Fmoc protecting group is subjected to crystallization, filtration and washing before removal of the Fmoc protecting group, and the Fmoc protecting group is removed, followed by crystallization, filtration and washing with acetonitrile.
  • step 6 after removing the protecting group, crystallization, centrifugation and washing are carried out with methanol.
  • liquid non-peptide liquid preparation method comprises the following steps:
  • step 6) The crude nano-peptide obtained in step 6) is prepared by reverse-phase high-performance liquid phase purification; the reverse phase octadecylsilane is used as a stationary phase, and the target peak fraction is collected by using 0.1% aqueous acetic acid/acetonitrile as a mobile phase, and concentrated. Freeze-dried, denapeptide.
  • the process of the present invention is suitable for industrial preparation, and the yield is improved as compared to the solid phase synthesis process efficiency and productivity.
  • the crude peptide obtained in Example 6 was prepared by reverse phase high performance liquid phase purification.
  • the reverse phase octadecylsilane was used as the stationary phase, and the target peak fraction was collected with 0.1% aqueous acetic acid/acetonitrile as the mobile phase, and concentrated to freeze to obtain 8.8 g (9.5 mmol) of pure product, the yield was 90%, and the purity was more than 99. %.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is a nano-nemifitide liquid phase preparation method comprising the following steps: 1) preparing intermediate 1H-Trp(Boc)-NH-Dpm with Dpm-NH2 and Fmoc-Trp(Boc)-OH; 2) preparing intermediate 2H-Gly-Trp(Boc)-NH-Dpm; 3) preparing intermediate 3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm; 4) preparing intermediate 4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm; 5) preparing intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm; 6) preparing a crude product of nano-nemifitide; and 7) preparing nano-nemifitide by reversed phase chromatography.

Description

一种奈米非肽液相制备方法Nano non-peptide liquid preparation method 技术领域Technical field
本发明涉及医药领域,具体涉及奈米非肽液相制备方法。The invention relates to the field of medicine, in particular to a method for preparing a liquid phase of nano-nonpeptide.
背景技术Background technique
单相抑郁是一种常见的由于中枢神经系统化学物质变化产生的精神紊乱,属于内源性抑郁症。使用抗抑郁药物治疗单相抑郁在医学界已经得到广泛认可。奈米非肽是一种脑内源性多肽MIF-1的类似物,可通过作用5-HT再摄取而发挥抗单相抑郁作用,极大改变了5-HT的再摄取,作用快,可通过血脑屏障,且在脑内清除较慢。目前美国InnapMarma公司正在进行III期临床试验,其抗抑郁活性和安全性已得到临床证实。Single-phase depression is a common mental disorder caused by changes in chemical substances in the central nervous system and belongs to endogenous depression. The use of antidepressants to treat unipolar depression has been widely recognized in the medical community. Nano-peptide is an analog of the brain endogenous polypeptide MIF-1, which can exert anti-monophasic depression by 5-HT reuptake, which greatly changes the reuptake of 5-HT. Pass the blood-brain barrier and clear it slowly in the brain. At present, the US company InnapMarma is conducting Phase III clinical trials, and its antidepressant activity and safety have been clinically confirmed.
奈米非肽,英文名:nemifitide;分子式:C33H43FN10O6;CAS:173240-15-8;是一种人工合成的五肽化合物,结构为4-氟-L-苯丙氨酰-(反式)4-羟基-L-脯氨酰-L-精氨酰-甘氨酰-L-色氨酰胺,见下图:Nano-peptide, English name: nemifitide; molecular formula: C 33 H 43 FN 10 O 6 ; CAS: 173240-15-8; is a synthetic pentapeptide compound, the structure is 4-fluoro-L-phenylalanine Acyl-(trans) 4-hydroxy-L-prolyl-L-arginyl-glycyl-L-tryptophan, see below:
Figure PCTCN2017092716-appb-000001
Figure PCTCN2017092716-appb-000001
目前,奈米非肽的合成方法在国内外少有报道,原研专利报道了奈米非肽固相合成方法(US5589460,WO1995030430A1),此方法是以Fmoc保护的氨基酸为反应原料,采用氨基树脂依次偶联,裂解后得到的粗肽经过HPLC纯化得到产品。经过本发明人研究发现,原研专利的方法可以得到合格产品,总收率只有40%。分析原因主要有以下几点:裂解后的粗肽产品纯度低,片段缺失肽杂质多,因此纯化收率不高,不适合规模化生产。At present, there are few reports on the synthesis of nano-peptides at home and abroad. The original research patent reported a nanophase non-peptide solid phase synthesis method (US5589460, WO1995030430A1), which uses Fmoc-protected amino acids as the reaction raw materials, using amino resin in turn. Coupling, the crude peptide obtained after cleavage was purified by HPLC to obtain a product. According to the research of the present inventors, the original patented method can obtain qualified products, and the total yield is only 40%. The main reasons for the analysis are as follows: the crude peptide product after cleavage has low purity, and the fragment lacks peptide impurities, so the purification yield is not high and is not suitable for large-scale production.
发明内容Summary of the invention
本发明的目的是提供一种奈米非肽的液相制备方法,该方法合成条件温和、工艺简单且工艺稳定,适合工业化连续生产。The object of the present invention is to provide a liquid phase preparation method of nano-peptide, which has mild synthesis conditions, simple process and stable process, and is suitable for industrial continuous production.
合成路线图如下所示: The synthetic route map is as follows:
Figure PCTCN2017092716-appb-000002
Figure PCTCN2017092716-appb-000002
本发明奈米非肽的制备方法,包括以下步骤:The preparation method of the nano-peptide of the invention comprises the following steps:
1)以Dpm-NH2和Fmoc-Trp(Boc)-OH制备中间体1H-Trp(Boc)-NH-Dpm;1) Preparation of intermediate 1H-Trp(Boc)-NH-Dpm with Dpm-NH 2 and Fmoc-Trp(Boc)-OH;
2)制备中间体2H-Gly-Trp(Boc)-NH-Dpm;2) Preparation of intermediate 2H-Gly-Trp(Boc)-NH-Dpm;
3)制备中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;3) Preparation of intermediate 3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
4)制备中间体4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;4) Preparation of intermediate 4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
5)制备中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;5) Preparation of intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
6)制备奈米非肽粗品;6) preparing a crude nanopeptide;
7)反相色谱制备奈米非肽。 7) Reverse phase chromatography to prepare nanopeptide.
具体地,本发明一个方面提供了一种奈米非肽液相制备方法,其包括如下步骤,Specifically, an aspect of the present invention provides a method for preparing a liquid phase of nano-nonpeptide, which comprises the following steps:
1)以Dpm-NH2和Fmoc-Trp(Boc)-OH在缩合剂的作用下合成Fmoc-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体1H-Trp(Boc)-NH-Dpm;1) Fmoc-Trp(Boc)-NH-Dpm was synthesized by Dpm-NH 2 and Fmoc-Trp(Boc)-OH under the action of a condensing agent, and the Fmoc protecting group was removed to obtain the intermediate 1H-Trp(Boc)- NH-Dpm;
2)以中间体1H-Trp(Boc)-NH-Dpm和Fmoc-Gly-OH在缩合剂的作用下合成Fmoc-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体2H-Gly-Trp(Boc)-NH-Dpm;2) The intermediates 1H-Trp(Boc)-NH-Dpm and Fmoc-Gly-OH were used to synthesize Fmoc-Gly-Trp(Boc)-NH-Dpm under the action of a condensing agent, and the Fmoc protecting group was removed to obtain an intermediate. 2H-Gly-Trp(Boc)-NH-Dpm;
3)以中间体2和Fmoc-Arg(Pbf)-OH在缩合剂的作用下合成Fmoc-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;3) Synthesis of Fmoc-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm by intermediate 2 and Fmoc-Arg(Pbf)-OH under the action of a condensing agent, removing the Fmoc protecting group to obtain intermediate 3H -Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
4)以中间体3和Fmoc-4-hydropro(OtBu)-OH在缩合剂的作用下合成Fmoc-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;4) Synthesis of Fmoc-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm by intermediate 3 and Fmoc-4-hydropro(OtBu)-OH under the action of a condensing agent In addition to the Fmoc protecting group, the intermediate 4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm is obtained;
5)以中间体4和Fmoc-4-Fphe-OH在缩合剂的作用下合成Fmoc-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;5) Synthesis of Fmoc-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm by intermediate 4 and Fmoc-4-Fphe-OH under the action of a condensing agent, Removal of the Fmoc protecting group to obtain the intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
6)脱除OtBu、Pbf和Boc保护基。6) Removal of OtBu, Pbf and Boc protecting groups.
在本发明的技术方案中,所述缩合剂选自HOBt、EDC.HCl、HATU、DCC、DIC、HBTU、HOAt、HOBt、PyBOP、BTC中的一种或多种,优选为HOBt和EDC.HCl的组合。In the technical solution of the present invention, the condensing agent is selected from one or more of HOBt, EDC.HCl, HATU, DCC, DIC, HBTU, HOAt, HOBt, PyBOP, BTC, preferably HOBt and EDC.HCl The combination.
在本发明的技术方案中,脱除Fmoc保护基的试剂为DBU与二乙胺的混合液In the technical solution of the present invention, the reagent for removing the Fmoc protecting group is a mixture of DBU and diethylamine.
在本发明的技术方案中,步骤6)中,脱保护基试剂为为TFA、H2O、EDT、PhOMe、苯甲硫醚的混合物;优选为,TFA:H2O:EDT:PhOMe=90-95:1-5:1-5:3-8,更优选为TFA:H2O:EDT:PhOMe=92:2:2:4。In the technical solution of the present invention, in the step 6), the deprotecting reagent is a mixture of TFA, H 2 O, EDT, PhOMe, thioanisole; preferably, TFA: H 2 O: EDT: PhOMe = 90 -95: 1-5: 1-5: 3-8, more preferably TFA: H 2 O: EDT: PhOMe = 92: 2: 2: 4.
在本发明的技术方案中,其还包括纯化步骤,所述纯化步骤位为7),In the technical solution of the present invention, the method further comprises a purification step, wherein the purification step is 7),
7)反相色谱进行纯化,优选地,反相高压液相色谱法为以反相十八烷基硅烷为固定相,以0.1%醋酸水溶液/乙腈为流动相,收集目的峰馏分,浓缩冻干。7) Purification by reverse phase chromatography. Preferably, reverse phase high pressure liquid chromatography is carried out by using reverse phase octadecylsilane as a stationary phase and 0.1% aqueous acetic acid/acetonitrile as a mobile phase to collect a peak fraction of interest and lyophilizing. .
在本发明的技术方案中,步骤1)-5)中的溶剂独立地选自二氯甲烷、三氯甲烷、甲苯中的一种或多种,优选为三氯甲烷。In a solution of the invention, the solvent in steps 1) to 5) is independently selected from one or more of dichloromethane, chloroform, toluene, preferably chloroform.
在本发明的技术方案中,步骤1)-5)中,脱除Fmoc保护基前以甲醇进行析晶、过滤和清洗,脱除Fmoc保护基后以乙腈进行析晶、过滤和清洗。In the technical solution of the present invention, in the steps 1) to 5), the Fmoc protecting group is subjected to crystallization, filtration and washing before removal of the Fmoc protecting group, and the Fmoc protecting group is removed, followed by crystallization, filtration and washing with acetonitrile.
在本发明的技术方案中,步骤6)中,脱除保护基后,以甲醇进行析晶、离心和清洗。In the technical solution of the present invention, in step 6), after removing the protecting group, crystallization, centrifugation and washing are carried out with methanol.
在本发明的技术方案中,所述的奈米非肽液相制备方法包括以下步骤: In the technical solution of the present invention, the liquid non-peptide liquid preparation method comprises the following steps:
1)将Dpm-NH2和Fmoc-Trp(Boc)-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体1H-Trp(Boc)-NH-Dpm;1) Dpm-NH 2 and Fmoc-Trp(Boc)-OH are dissolved in CHCl 3 , HOBt, EDC.HCl is added, the reaction is completed to complete, the solvent is removed, methanol is added, the solid is precipitated, and the solid is washed with methanol and dissolved. Chloroform, DBU, diethylamine was added in sequence, the reaction was completed, the solvent was removed, acetonitrile was added to the residue, and the solid was precipitated, filtered, washed with acetonitrile and dried to give intermediate 1H-Trp(Boc)-NH-Dpm;
2)将中间体1H-Trp(Boc)-NH-Dpm和Fmoc-Gly-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体2H-Gly-Trp(Boc)-NH-Dpm;2) The intermediates 1H-Trp(Boc)-NH-Dpm and Fmoc-Gly-OH are dissolved in CHCl 3 , HOBt, EDC.HCl are added, the reaction is completed to complete, the solvent is removed, methanol is added, the solid is precipitated, and the solid is filtered. After washing with methanol, it is dissolved in chloroform, DBU and diethylamine are added successively, the reaction is completed to completeness, the solvent is removed, acetonitrile is added to the residue, solid is precipitated, filtered, washed with acetonitrile and dried to give intermediate 2H-Gly-Trp (Boc). -NH-Dpm;
3)将中间体2H-Gly-Trp(Boc)-NH-Dpm和Fmoc-Arg(Pbf)-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;3) The intermediate 2H-Gly-Trp(Boc)-NH-Dpm and Fmoc-Arg(Pbf)-OH are dissolved in CHCl 3 , HOBt, EDC.HCl is added, the reaction is completed, the solvent is removed, methanol is added, and solid is precipitated. After filtration, the solid is washed with methanol, dissolved in chloroform, and then DBU and diethylamine are added to the reaction. The solvent is completely removed. The solvent is removed and the residue is added with acetonitrile. The solid is precipitated, filtered, washed with acetonitrile and dried to give intermediate 3H-Arg. (Pbf)-Gly-Trp(Boc)-NH-Dpm;
4)将中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm和Fmoc-4-hydropro(OtBu)-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;4) Dissolve the intermediate 3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm and Fmoc-4-hydropro(OtBu)-OH in CHCl 3 , add HOBt, EDC.HCl, and react to complete Solvent, add methanol, precipitate solids, filter, solids are washed with methanol, dissolved in chloroform, DBU, diethylamine are added in sequence, the reaction is complete, solvent is removed, acetonitrile is added to the residue, solid is precipitated, filtered, washed with acetonitrile and dried , intermediate H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
5)将中间体H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm和Fmoc-4-Fphe-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;5) The intermediates H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm and Fmoc-4-Fphe-OH are dissolved in CHCl 3 , and HOBt, EDC.HCl are added to react. To complete, remove the solvent, add methanol, precipitate the solid, filter, wash the solid with methanol, dissolve in chloroform, add DBU, diethylamine in sequence, complete the reaction, remove the solvent, add acetonitrile to the residue, precipitate solid, filter, The acetonitrile is washed and dried to obtain the intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
6)将中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm溶解于TFA:H2O:EDT:PhOMe=92:2:2:4混合溶液中,反应至完全,将滤液缓慢加入冰乙醚中沉淀、离心、以冰乙醚清洗并干燥得奈米非肽粗品;6) Dissolve the intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm in TFA:H 2 O:EDT:PhOMe=92:2:2 : 4 mixed solution, the reaction was completed, the filtrate was slowly added to ice diethyl ether precipitation, centrifugation, washed with ice diethyl ether and dried to obtain crude naphthopeptide;
7)将步骤6)所得奈米非肽粗品用反相高效液相纯化制备;以反相十八烷基硅烷为固定相,以0.1%醋酸水溶液/乙腈为流动相,收集目的峰馏分,浓缩冻干,得奈米非肽。7) The crude nano-peptide obtained in step 6) is prepared by reverse-phase high-performance liquid phase purification; the reverse phase octadecylsilane is used as a stationary phase, and the target peak fraction is collected by using 0.1% aqueous acetic acid/acetonitrile as a mobile phase, and concentrated. Freeze-dried, denapeptide.
有益效果Beneficial effect
本发明的方法适合工业上制备,产率相比于固相合成方法效率和产率均有较高的提高。The process of the present invention is suitable for industrial preparation, and the yield is improved as compared to the solid phase synthesis process efficiency and productivity.
具体实施方式 detailed description
实施例1中间体1H-Trp(Boc)-NH-Dpm的制备Example 1 Preparation of Intermediate 1H-Trp(Boc)-NH-Dpm
将Dpm-NH2(14.4mmol)、Fmoc-Trp(Boc)-OH(16.2mmol)加入到反应器中,用CHCl3(150mL)溶解,然后加入HOBt(14.4mol)、EDC.HCl(28.8mmol)。混合液搅拌反应3小时,TLC点板检测反应结束。减压蒸除溶剂,加入甲醇120mL,析出固体,过滤,固体用甲醇200mL洗三遍。将固体溶解于150mL氯仿中,依次加入DBU(14.4mmol)、二乙胺150(mmol),搅拌反应1小时,反应结束。减压蒸除溶剂,剩余物中加入乙腈50mL,析出固体,过滤。固体用乙腈50mL洗三次,减压干燥得中间体1H-Trp(Boc)-NH-Dpm14.0mmol,收率97%。Dpm-NH 2 (14.4 mmol), Fmoc-Trp (Boc)-OH (16.2 mmol) was added to the reactor, dissolved in CHCl 3 (150 mL), then HOBt (14.4 mol), EDC.HCl (28.8 mmol) was added. ). The mixture was stirred for 3 hours, and the reaction was terminated by TLC dot plate. The solvent was evaporated under reduced pressure, and methanol (120 mL) was added, and the solid was precipitated, filtered, and the solid was washed three times with 200 mL of methanol. The solid was dissolved in 150 mL of chloroform, and DBU (14.4 mmol) and diethylamine 150 (mmol) were successively added, and the reaction was stirred for 1 hour, and the reaction was completed. The solvent was evaporated under reduced pressure, and EtOAc (50 mL). The solid was washed three times with 50 mL of acetonitrile, and dried under reduced pressure to give Intermediate 1H-Trp(Boc)-NH-D.
实施例2中间体2H-Gly-Trp(Boc)-NH-Dpm的制备Example 2 Preparation of Intermediate 2H-Gly-Trp(Boc)-NH-Dpm
将实施例1制得的中间体1H-Trp(Boc)-NH-Dpm14.0mmol、Fmoc-Gly-OH14.0mmol加入到反应器中,用CHCl3(150mL)溶解,然后加入HOBt(14.0mol)、EDC.HCl(28.0mmol)。混合液搅拌反应3小时,TLC点板检测反应结束。减压蒸除溶剂,加入甲醇120mL,析出固体,过滤,固体用甲醇200mL洗三遍。将固体溶解于150mL氯仿中,依次加入DBU(14.0mmol)、二乙胺150(mmol),搅拌反应1小时,反应结束。减压蒸除溶剂,剩余物中加入乙腈50mL,析出固体,过滤。固体用乙腈50mL洗三次,减压干燥得中间体2H-Gly-Trp(Boc)-NH-Dpm13.8mmol,收率99%。The intermediate 1H-Trp(Boc)-NH-Dpm14.0 mmol, Fmoc-Gly-OH14.0 mmol prepared in Example 1 was added to the reactor, dissolved in CHCl 3 (150 mL), and then HOBt (14.0 mol) was added. , EDC.HCl (28.0 mmol). The mixture was stirred for 3 hours, and the reaction was terminated by TLC dot plate. The solvent was evaporated under reduced pressure, and methanol (120 mL) was added, and the solid was precipitated, filtered, and the solid was washed three times with 200 mL of methanol. The solid was dissolved in 150 mL of chloroform, and DBU (14.0 mmol) and diethylamine 150 (mmol) were successively added, and the reaction was stirred for 1 hour, and the reaction was completed. The solvent was evaporated under reduced pressure, and EtOAc (50 mL). The solid was washed three times with 50 mL of acetonitrile and dried under reduced pressure to give Intermediate 2H-Gly-Trp(Boc)-NH-Dpm 13.8 mmol.
实施例3中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm的制备Example 3 Preparation of Intermediate 3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm
将实施例2制得的中间体2H-Gly-Trp(Boc)-NH-Dpm13.8mmol、Fmoc-Arg(Pbf)-OH13.8mmol加入到反应器中,用CHCl3(150mL)溶解,然后加入HOBt(13.8mol)、EDC.HCl(28.0mmol)。混合液搅拌反应3小时,TLC点板检测反应结束。减压蒸除溶剂,加入甲醇120mL,析出固体,过滤,固体用甲醇200mL洗三遍。将固体溶解于150mL氯仿中,依次加入DBU(13.8mmol)、二乙胺150(mmol),搅拌反应1小时,反应结束。减压蒸除溶剂,剩余物中加入乙腈50mL,析出固体,过滤。固体用乙腈50mL洗三次,减压干燥得中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm13.6mmol,收率99%。The intermediate 2H-Gly-Trp(Boc)-NH-Dpm 13.8 mmol, Fmoc-Arg(Pbf)-OH 13.8 mmol prepared in Example 2 was added to the reactor, dissolved in CHCl 3 (150 mL), and then added. HOBt (13.8 mol), EDC.HCl (28.0 mmol). The mixture was stirred for 3 hours, and the reaction was terminated by TLC dot plate. The solvent was evaporated under reduced pressure, and methanol (120 mL) was added, and the solid was precipitated, filtered, and the solid was washed three times with 200 mL of methanol. The solid was dissolved in 150 mL of chloroform, and DBU (13.8 mmol) and diethylamine 150 (mmol) were successively added, and the reaction was stirred for 1 hour, and the reaction was completed. The solvent was evaporated under reduced pressure, and EtOAc (50 mL). The solid was washed three times with 50 mL of acetonitrile, and dried under reduced pressure to give Intermediate 3H- s(Pbf)-Gly-Trp(Boc)-NH-Dpm 13.6 mmol, yield 99%.
实施例4中间体4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm的制备 Example 4 Preparation of Intermediate 4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm
将中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm13.6mmol、Fmoc-4-hydropro(OtBu)-OH13.6mmol加入到反应器中,用CHCl3(130mL)溶解,然后加入HOBt(13.6mol)、EDC.HCl(27.8mmol)。混合液搅拌反应3小时,TLC点板检测反应结束。减压蒸除溶剂,加入甲醇120mL,析出固体,过滤,固体用甲醇200mL洗三遍。将固体溶解于150mL氯仿中,依次加入DBU(13.6mmol)、二乙胺145(mmol),搅拌反应1小时,反应结束。减压蒸除溶剂,剩余物中加入乙腈50mL,析出固体,过滤。固体用乙腈50mL洗三次,减压干燥得中间体4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm 13.0mmol,收率95%。The intermediate 3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm13.6mmol, Fmoc-4-hydropro(OtBu)-OH13.6mmol was added to the reactor, dissolved in CHCl 3 (130 mL), and then HOBt (13.6 mol), EDC.HCl (27.8 mmol) was added. The mixture was stirred for 3 hours, and the reaction was terminated by TLC dot plate. The solvent was evaporated under reduced pressure, and methanol (120 mL) was added, and the solid was precipitated, filtered, and the solid was washed three times with 200 mL of methanol. The solid was dissolved in 150 mL of chloroform, and DBU (13.6 mmol) and diethylamine 145 (mmol) were successively added, and the reaction was stirred for 1 hour, and the reaction was completed. The solvent was evaporated under reduced pressure, and EtOAc (50 mL). The solid was washed three times with 50 mL of acetonitrile, and dried under reduced pressure to give Intermediate 4H-4-hydropro(OtBu)- </RTI> (Pbf)-Gly-Trp(Boc)-NH-Dpm 13.0 mmol, yield 95%.
实施例5中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm的制备Example 5 Preparation of intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm
将中间体4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm 13.0mmol、Fmoc-4-Fphe-OH13.0mmol加入到反应器中,用CHCl3(140mL)溶解,然后加入HOBt(13.0mol)、EDC.HCl(27.5mmol)。混合液搅拌反应3小时,TLC点板检测反应结束。减压蒸除溶剂,加入甲醇120mL,析出固体,过滤,固体用甲醇200mL洗三遍。将固体溶解于150mL氯仿中,依次加入DBU(13.0mmol)、二乙胺140(mmol),搅拌反应1小时,反应结束。减压蒸除溶剂,剩余物中加入乙腈50mL,析出固体,过滤。固体用乙腈50mL洗三次,减压干燥得中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm12.5mmol,收率96%。Add intermediate 4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm 13.0 mmol, Fmoc-4-Fphe-OH 13.0 mmol to the reactor with CHCl 3 (140 mL) Dissolved, then HOBt (13.0 mol), EDC.HCl (27.5 mmol) was added. The mixture was stirred for 3 hours, and the reaction was terminated by TLC dot plate. The solvent was evaporated under reduced pressure, and methanol (120 mL) was added, and the solid was precipitated, filtered, and the solid was washed three times with 200 mL of methanol. The solid was dissolved in 150 mL of chloroform, and DBU (13.0 mmol) and diethylamine 140 (mmol) were successively added, and the reaction was stirred for 1 hour, and the reaction was completed. The solvent was evaporated under reduced pressure, and EtOAc (50 mL). The solid was washed three times with 50 mL of acetonitrile and dried under reduced pressure to give Intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm 12.5 mmol.
实施例6奈米非肽粗品的制备Example 6 Preparation of crude nanopeptides
将实施例5制得的中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm12.5mmol溶解于TFA:H2O:EDT:PhOMe=92:2:2:4混合溶液20ml中,室温反应2小时,将滤液缓慢加入200ml冰乙醚中沉淀。离心,冰乙醚洗涤5次,减压干燥得到奈米非肽粗品10.5mmol,收率85%。The intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm12.5 mmol prepared in Example 5 was dissolved in TFA:H 2 O:EDT:PhOMe =92:2:2:4 In a mixed solution of 20 ml, the mixture was reacted at room temperature for 2 hours, and the filtrate was slowly added to 200 ml of ice diethyl ether to precipitate. The mixture was centrifuged, washed with ice diethyl ether for 5 times, and dried under reduced pressure to give 10.5 mmol of crude crude crude crystals.
实施例7奈米非肽的制备Example 7 Preparation of Nano-Peptide
将实施例6得到的粗肽用反相高效液相纯化制备。以反相十八烷基硅烷为固定相,以0.1%醋酸水溶液/乙腈为流动相,收集目的峰馏分,浓缩冻干,得纯品8.8g(9.5mmol),收率90%,纯度大于99%。The crude peptide obtained in Example 6 was prepared by reverse phase high performance liquid phase purification. The reverse phase octadecylsilane was used as the stationary phase, and the target peak fraction was collected with 0.1% aqueous acetic acid/acetonitrile as the mobile phase, and concentrated to freeze to obtain 8.8 g (9.5 mmol) of pure product, the yield was 90%, and the purity was more than 99. %.
缩写及英文Abbreviation and English 含义meaning
DpmDpm 双(4-二十二烷氧基苯基)甲基Bis(4-docosyloxyphenyl)methyl
FmocFmoc 9-芴甲氧羰基9-fluorenylmethoxycarbonyl
HOBtHOBt 1-羟基苯并三唑1-hydroxybenzotriazole
EDC·HClEDC·HCl 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐1-ethyl-(3-dimethylaminopropyl)carbonyldiimide hydrochloride
TFATFA 三氟乙酸Trifluoroacetate
TATA 苯甲硫醚Benzoyl sulfide
PhOMePhOMe 苯甲醚Anisole
EDTEDT 乙二硫醇Ethylenedithiol
tButBu 叔丁基Tert-butyl
OtBuOtBu 叔丁酯Tert-butyl ester

Claims (9)

  1. 一种奈米非肽液相制备方法,其包括如下步骤,A method for preparing a liquid phase of nano-nonpeptide, which comprises the following steps,
    1)以Dpm-NH2和Fmoc-Trp(Boc)-OH在缩合剂的作用下合成Fmoc-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体1H-Trp(Boc)-NH-Dpm;1) Fmoc-Trp(Boc)-NH-Dpm was synthesized by Dpm-NH 2 and Fmoc-Trp(Boc)-OH under the action of a condensing agent, and the Fmoc protecting group was removed to obtain the intermediate 1H-Trp(Boc)- NH-Dpm;
    2)以中间体1H-Trp(Boc)-NH-Dpm和Fmoc-Gly-OH在缩合剂的作用下合成Fmoc-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体2H-Gly-Trp(Boc)-NH-Dpm;2) The intermediates 1H-Trp(Boc)-NH-Dpm and Fmoc-Gly-OH were used to synthesize Fmoc-Gly-Trp(Boc)-NH-Dpm under the action of a condensing agent, and the Fmoc protecting group was removed to obtain an intermediate. 2H-Gly-Trp(Boc)-NH-Dpm;
    3)以中间体2和Fmoc-Arg(Pbf)-OH在缩合剂的作用下合成Fmoc-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;3) Synthesis of Fmoc-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm by intermediate 2 and Fmoc-Arg(Pbf)-OH under the action of a condensing agent, removing the Fmoc protecting group to obtain intermediate 3H -Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
    4)以中间体3和Fmoc-4-hydropro(OtBu)-OH在缩合剂的作用下合成Fmoc-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;4) Synthesis of Fmoc-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm by intermediate 3 and Fmoc-4-hydropro(OtBu)-OH under the action of a condensing agent In addition to the Fmoc protecting group, the intermediate 4H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm is obtained;
    5)以中间体4和Fmoc-4-Fphe-OH在缩合剂的作用下合成Fmoc-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm,脱除Fmoc保护基,获得中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;5) Synthesis of Fmoc-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm by intermediate 4 and Fmoc-4-Fphe-OH under the action of a condensing agent, Removal of the Fmoc protecting group to obtain the intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
    6)脱除OtBu、Pbf和Boc保护基。6) Removal of OtBu, Pbf and Boc protecting groups.
  2. 根据权利要求1所述的奈米非肽液相制备方法,其中所述的缩合剂选自HOBt、EDC.HCl、HATU、DCC、DIC、HBTU、HOAt、HOBt、PyBOP、BTC中的一种或多种,优选为HOBt和EDC.HCl的组合。The method for preparing a liquid phase of nano-peptide according to claim 1, wherein the condensing agent is selected from one of HOBt, EDC.HCl, HATU, DCC, DIC, HBTU, HOAt, HOBt, PyBOP, BTC or A plurality, preferably a combination of HOBt and EDC.HCl.
  3. 根据权利要求1所述的奈米非肽液相制备方法,脱除Fmoc保护基的试剂为DBU与二乙胺的混合液。The method for preparing a liquid phase of nano-peptide according to claim 1, wherein the reagent for removing the Fmoc protecting group is a mixture of DBU and diethylamine.
  4. 根据权利要求1所述的奈米非肽液相制备方法,步骤6)中,脱保护基试剂为为TFA、H2O、EDT、PhOMe、苯甲硫醚的混合物;优选为,TFA:H2O:EDT:PhOMe=90-95:1-5:1-5:3-8,更优选为TFA:H2O:EDT:PhOMe=92:2:2:4。The method for preparing a liquid phase of nano-peptide according to claim 1, wherein in step 6), the deprotecting agent is a mixture of TFA, H 2 O, EDT, PhOMe, thioanisole; preferably, TFA: H 2 O: EDT: PhOMe = 90-95: 1-5: 1-5: 3-8, more preferably TFA: H 2 O: EDT: PhOMe = 92: 2: 2: 4.
  5. 根据权利要求1所述的奈米非肽液相制备方法,其还包括纯化步骤,所述纯化步骤为7),The method for preparing a liquid phase of nanopeptide according to claim 1, further comprising a purification step, wherein the purification step is 7),
    7)反相色谱进行纯化,优选地,反相高压液相色谱法为以反相十八烷基硅烷为固定相,以0.1%醋酸水溶液/乙腈为流动相,收集目的峰馏分,浓缩冻干。7) Purification by reverse phase chromatography. Preferably, reverse phase high pressure liquid chromatography is carried out by using reverse phase octadecylsilane as a stationary phase and 0.1% aqueous acetic acid/acetonitrile as a mobile phase to collect a peak fraction of interest and lyophilizing. .
  6. 根据权利要求1所述的奈米非肽液相制备方法,步骤1)-5)中的溶剂独立地选自二氯甲烷、三氯甲烷、甲苯中的一种或多种,优选为三氯甲烷。 The method for preparing a liquid phase of nano-peptide according to claim 1, wherein the solvent in steps 1) to 5) is independently selected from one or more of dichloromethane, chloroform and toluene, preferably trichlorobenzene. Methane.
  7. 根据权利要求1所述的奈米非肽液相制备方法,步骤1)-5)中,脱除Fmoc保护基前以甲醇进行析晶、过滤和清洗,脱除Fmoc保护基后以乙腈进行析晶、过滤和清洗。The method for preparing a liquid phase of nano-peptide according to claim 1, wherein in the steps 1) to 5), the Fmoc protecting group is removed by crystallization, filtration and washing, and the Fmoc protecting group is removed and then analyzed by acetonitrile. Crystal, filtration and cleaning.
  8. 根据权利要求1所述的奈米非肽液相制备方法,步骤6)中,脱除保护基后,以甲醇进行析晶、离心和清洗。The method for preparing a liquid phase of nano-peptide according to claim 1, wherein in step 6), after removing the protecting group, crystallization, centrifugation and washing are carried out with methanol.
  9. 根据权利要求1所述的奈米非肽液相制备方法,The method for preparing a liquid phase of nano-peptide according to claim 1,
    1)将Dpm-NH2和Fmoc-Trp(Boc)-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体1H-Trp(Boc)-NH-Dpm;1) Dpm-NH 2 and Fmoc-Trp(Boc)-OH are dissolved in CHCl 3 , HOBt, EDC.HCl is added, the reaction is completed to complete, the solvent is removed, methanol is added, the solid is precipitated, and the solid is washed with methanol and dissolved. Chloroform, DBU, diethylamine was added in sequence, the reaction was completed, the solvent was removed, acetonitrile was added to the residue, and the solid was precipitated, filtered, washed with acetonitrile and dried to give intermediate 1H-Trp(Boc)-NH-Dpm;
    2)将中间体1H-Trp(Boc)-NH-Dpm和Fmoc-Gly-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体2H-Gly-Trp(Boc)-NH-Dpm;2) The intermediates 1H-Trp(Boc)-NH-Dpm and Fmoc-Gly-OH are dissolved in CHCl 3 , HOBt, EDC.HCl are added, the reaction is completed to complete, the solvent is removed, methanol is added, the solid is precipitated, and the solid is filtered. After washing with methanol, it is dissolved in chloroform, DBU and diethylamine are added successively, the reaction is completed to completeness, the solvent is removed, acetonitrile is added to the residue, solid is precipitated, filtered, washed with acetonitrile and dried to give intermediate 2H-Gly-Trp (Boc). -NH-Dpm;
    3)将中间体2H-Gly-Trp(Boc)-NH-Dpm和Fmoc-Arg(Pbf)-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;3) The intermediate 2H-Gly-Trp(Boc)-NH-Dpm and Fmoc-Arg(Pbf)-OH are dissolved in CHCl 3 , HOBt, EDC.HCl is added, the reaction is completed, the solvent is removed, methanol is added, and solid is precipitated. After filtration, the solid is washed with methanol, dissolved in chloroform, and then DBU and diethylamine are added to the reaction. The solvent is completely removed. The solvent is removed and the residue is added with acetonitrile. The solid is precipitated, filtered, washed with acetonitrile and dried to give intermediate 3H-Arg. (Pbf)-Gly-Trp(Boc)-NH-Dpm;
    4)将中间体3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm和Fmoc-4-hydropro(OtBu)-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;4) Dissolve the intermediate 3H-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm and Fmoc-4-hydropro(OtBu)-OH in CHCl 3 , add HOBt, EDC.HCl, and react to complete Solvent, add methanol, precipitate solids, filter, solids are washed with methanol, dissolved in chloroform, DBU, diethylamine are added in sequence, the reaction is complete, solvent is removed, acetonitrile is added to the residue, solid is precipitated, filtered, washed with acetonitrile and dried , intermediate H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
    5)将中间体H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm和Fmoc-4-Fphe-OH以CHCl3溶解,加入HOBt、EDC.HCl,反应至完全,去除溶剂,加入甲醇,析出固体、过滤,固体以甲醇清洗后溶解于氯仿,依次加入DBU、二乙胺,反应至完全,去除溶剂,剩余物中加入乙腈,析出固体、过滤、以乙腈清洗并干燥,得中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;5) The intermediates H-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm and Fmoc-4-Fphe-OH are dissolved in CHCl 3 , and HOBt, EDC.HCl are added to react. To complete, remove the solvent, add methanol, precipitate the solid, filter, wash the solid with methanol, dissolve in chloroform, add DBU, diethylamine in sequence, complete the reaction, remove the solvent, add acetonitrile to the residue, precipitate solid, filter, The acetonitrile is washed and dried to obtain the intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm;
    6)将中间体5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm溶解于TFA:H2O:EDT:PhOMe=92:2:2:4混合溶液中,反应至完全, 将滤液缓慢加入冰乙醚中沉淀、离心、以冰乙醚清洗并干燥得奈米非肽粗品;6) Dissolve the intermediate 5H-4-Fphe-4-hydropro(OtBu)-Arg(Pbf)-Gly-Trp(Boc)-NH-Dpm in TFA:H 2 O:EDT:PhOMe=92:2:2 : 4 mixed solution, the reaction was completed, the filtrate was slowly added to ice diethyl ether precipitation, centrifugation, washed with ice diethyl ether and dried to obtain a crude nanopeptide;
    7)将步骤6)所得奈米非肽粗品用反相高效液相纯化制备;以反相十八烷基硅烷为固定相,以0.1%醋酸水溶液/乙腈为流动相,收集目的峰馏分,浓缩冻干,得奈米非肽。 7) The crude nano-peptide obtained in step 6) is prepared by reverse-phase high-performance liquid phase purification; the reverse phase octadecylsilane is used as a stationary phase, and the target peak fraction is collected by using 0.1% aqueous acetic acid/acetonitrile as a mobile phase, and concentrated. Freeze-dried, denapeptide.
PCT/CN2017/092716 2017-04-07 2017-07-13 Nano-nemifitide liquid phase preparation method WO2018184316A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017102241006 2017-04-07
CN201710224100.6A CN108690121B (en) 2017-04-07 2017-04-07 A liquid phase method for preparing nano-sized non-peptide

Publications (1)

Publication Number Publication Date
WO2018184316A1 true WO2018184316A1 (en) 2018-10-11

Family

ID=63712555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/092716 WO2018184316A1 (en) 2017-04-07 2017-07-13 Nano-nemifitide liquid phase preparation method

Country Status (2)

Country Link
CN (1) CN108690121B (en)
WO (1) WO2018184316A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114524860A (en) * 2021-12-29 2022-05-24 深圳翰宇药业股份有限公司 Synthesis method and application of Etelcalcetide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1151700A (en) * 1994-05-04 1997-06-11 印纳药品股份有限公司 Tri-, tetra-, penta- and polypeptides and their therapeutic use as an antidepressant agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1151700A (en) * 1994-05-04 1997-06-11 印纳药品股份有限公司 Tri-, tetra-, penta- and polypeptides and their therapeutic use as an antidepressant agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN, YANLI: "Chemical Synthetic Research on Peptide Segments Ligation, Peptide Derivatives and Conjugate of Modifer-peptide Derivative", CMFD MEDICAL AND HEALTH SCIENCES, 15 May 2010 (2010-05-15), ISSN: 1674-0246 *

Also Published As

Publication number Publication date
CN108690121B (en) 2020-05-15
CN108690121A (en) 2018-10-23

Similar Documents

Publication Publication Date Title
JP6703668B2 (en) Peptide synthesis method
EP2873677B1 (en) Method of producing self-assembling peptide derivative
US8828938B2 (en) Method for the manufacture of degarelix
US9394341B2 (en) Eptifibatide preparation method
US20140187745A1 (en) Method for preparing bivalirudin
CN101372505B (en) Method for preparing desmopressin acetate
CN104844706A (en) Method for synthesizing lixisenatide
US10125164B2 (en) Process for preparing D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
WO2018184316A1 (en) Nano-nemifitide liquid phase preparation method
CN110642936B (en) Method for preparing teriparatide
WO2019218381A1 (en) Method for synthesizing etelcalcetide
CN113045623A (en) Liquid phase synthesis method of snake venom peptide SYN-AKE
CN113549130B (en) Liquid phase synthesis method of breast enlarging peptide
WO2021103458A1 (en) Solid-phase synthesis method for degarelix
WO2021026800A1 (en) Method for synthesizing degarelix acetate
WO2019127920A1 (en) Liquid phase spherical carrier, preparation method therefor and use thereof
US11332495B2 (en) Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
WO2009150657A1 (en) Improved process for preparation of eptifibatide by fmoc solid phase synthesis
CN109438363B (en) Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt
CN112125956A (en) Preparation method of degarelix
CN117586336A (en) Synthesis method and application of difficult polypeptide
CN107698663B (en) Liquid phase synthesis method of vilospiritide
CN114057829A (en) Solid-phase synthesis method of N-methylated polypeptide
CN114456236A (en) Preparation method of degarelix acetylated impurities
CN117683114A (en) Preparation method of thymalfasin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17904568

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17904568

Country of ref document: EP

Kind code of ref document: A1